Ibandronate Beneficial For Patients with Breast Cancer and Bone Metastases in Many Ways

.

Ibandronate Beneficial For Patients with Breast Cancer and Bone Metastases in Ma

As per a recent study, Ibandronate could prove as an effective treatment for relieving pain and is also safe to use by patients with breast cancer with metastatic bone disease (MBD).

The study conducted by Marcus Schmidt, MD, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, and colleagues analyzed impact of ibandronate on patients with breast cancer and MBD and suffering from severe pain, using analgesic and also estimated creatinine clearance in them.

There were involved more than 3,500 patients in the study and they were given ibandronate 6 mg IV for three to four weeks or they were put on a daily 50 mg dose of ibandronate. It was found that the problem of severe pain was reduced in around 64% of the total participants.

Dr. Schmidt said, "The data suggest that the analgesic efficacy and renal safety profile of IV and oral formulations of ibandronate seen in phase 3 trials transfers to routine clinical practice under real-life conditions".

Also, treatment with ibandronate made patients to depend less on analgesis and at the end of the study, 57% of the patients shunned using analgesic as compared to 54% who were at the baseline. The renal function was also found to be stable and no affects were casted by ibandronate treatment on them. There were only 7% cases of skeletal-related events (SREs) and the drug was considered as tolerated.


Latest News

Sea World Advertisement Says Killer Whales Live as Long in Captivity as in the W
Republican Senator, Ted Cruz to Compete for President’s Post; But Could his Birt
Ruth Porat to be Google’s New CFO
Fresh Competition Force Netflix, Hulu and Amazon to Look for New Technologies an
Cash-strapped Americans turn to Tax Refund Advances
Drone Manufacturers Have an Eye on North Dakota, Testing Ground for Unmanned Air
Tiffany’s Sales Decline due to a Strong Dollar
Bank of New York Mellon will settle Charges of Defrauding Customers for $714
Return Policy for Target’s Owned and Exclusive Brands Extended to One Year
Starbucks “Race Together” Idea Initiated by CEO Gets a Mixed Reaction
Brent Callinicos Uber’s CFO Steps Down to Spend More Time with Family
Even with the Perfect Design, Driverless Cars May Face Rare Circumstances that m